

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/331577633>

SMIM1 at a glance; discovery, genetic basis, recent progress and perspectives

Article · March 2019

DOI: 10.1016/j.parepi.2019.e00101

CITATIONS

0

READS

140

5 authors, including:



Yaw Aniweh

West Africa Centre for Cell Biology of Infectious Pathogens (WACCBIP), Ghana

31 PUBLICATIONS 75 CITATIONS

[SEE PROFILE](#)



Prince Berko Nyarko

University of Ghana

15 PUBLICATIONS 5 CITATIONS

[SEE PROFILE](#)



Evelyn Baaba Quansah

University of Ghana

1 PUBLICATION 0 CITATIONS

[SEE PROFILE](#)



Thiam Laty Gaye

University of Ghana

7 PUBLICATIONS 31 CITATIONS

[SEE PROFILE](#)


Some of the authors of this publication are also working on these related projects:



Search for the X receptor of *P. falciparum* [View project](#)



Invasion phenotype switching mechanisms in *P. falciparum* [View project](#)



SMIM1 at a glance; discovery, genetic basis, recent progress and perspectives

Yaw Aniweh^{a,*,1}, Prince B. Nyarko^{a,b,1}, Evelyn Quansah^{a,b},
Laty Gaye Thiam^{a,b}, Gordon A. Awandare^{a,b}

^a West Africa Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana

^b Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana

ARTICLE INFO

Article history:

Received 5 June 2018

Received in revised form 28 December 2018

Accepted 6 March 2019

Keywords:

Vel
Blood
Nucleotides
Frameshift
Heterozygous

ABSTRACT

Recent elucidation of the genetic basis of the Vel blood group system has offered the field of blood transfusion medicine an additional consideration in determining the causes of hemolytic reactions after a patient is transfused. The identification of the SMIM1 gene to be responsible for the Vel blood group allows molecular based tools to be developed to further dissect the function of this antigen. Genetic signatures such as the homozygous 17 bp deletion and the heterozygous 17 bp deletion in combination with other single nucleotide polymorphisms (SNPs) and insertion sequences regulate the expression level of the gene. With this knowledge, it is now possible to study this antigen in-depth.

© 2019 Published by Elsevier Ltd on behalf of World Federation of Parasitologists. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Contents

1. The Vel blood group	0
2. The genetic basis of the Vel blood group.	0
3. The SMIM1 protein	0
4. Vel blood group and health	0
5. Typing the Vel blood group	0
6. SMIM1 in the <i>Plasmodium falciparum</i> infection	0
7. Conclusion	0
Acknowledgments	0
References	0

1. The Vel blood group

The Vel blood group was first described in 1952 when a patient had a hemolytic reaction after a blood transfusion (Sussman and Miller, 1952; Storry and Peyrard, 2017). It was discovered that, except for her own blood, Mrs. Vel produced alloantibodies

* Corresponding author.

E-mail address: yaniweh@ug.edu.gh (Y. Aniweh).

¹ Authors contributed equally.

Table 1
SMIM1 alleles and their effect on gene expression.

SNP	Major/minor allele	Effects on SMIM1 expression
rs1184341	C/T	No
rs2797432	G/A	No
rs143702418	C/CGCA	Yes
rs1181893	C/A	No
rs6673829	G/A	No
rs1175550	A/G	Yes
rs9424296	C/A	No
rs1175549	A/C	No

SMIM1 is highly expressed in hematopoietic cells yet, the exact mechanism of its involvement in erythroid development is limited (Storry et al., 2013). The protein has been shown to undergo posttranslational modification through phosphorylation of serine residues at positions 6, 17, 22 and 27 (Arnaud et al., 2015) (Fig. 2c). As a protein, SMIM1 is conserved in primates. The degree of conservation of the extracellular domain is very high (approximately 100%), followed by the transmembrane domain (98%) and variable cytoplasmic tail (approximately 76%). It is however not clear what interactions this protein engages in at the interface of the cytoskeleton, in the cytosol or during cell-cell adhesion/communication. Additionally, the molecular basis of Vel is not entirely known. It is unclear whether the blood group is determined by the extracellular domain of SMIM1 or post-translational modifications on the protein surface. Thus, this gap in knowledge needs resolution.

4. Vel blood group and health

Vel is a high frequency blood group antigen with a negativity occurrence rate of approximately 0.025% in Caucasians (Cedergren et al., 1976; Herron et al., 1979; Daniels, 2013) similar to 0.021% in Brazil (Dezan et al., 2016). To date, available data suggest the prevalence of the Vel negative (Vel⁻) phenotype is highest in Caucasians, especially in the Scandinavia, while black Africans from Ethiopia, South Africa as well as black Americans show the lowest prevalence (Storry et al., 2013; Haer-Wigman et al., 2015a, 2015b). With these data, it is clear that Vel⁻ blood is difficult to obtain for the purpose of transfusion in many countries. The erythrocyte hemolytic activity induced by the anti-Vel response has been described as very aggressive (Sussman and Miller, 1952; Le Masne et al., 1992; Vucinovic et al., 2004; Van Gammeren et al., 2008). In neonates, three different reports have shown that anti-Vel is able to cause mild to severe neonatal hemolytic disease (Le Masne et al., 1992; Vucinovic et al., 2004; Van Gammeren et al., 2008). Despite the breakthrough on the underlying genetics of the Vel blood group, data on SMIM1 genetics is still limited. Presently, there are no data available for natives of Sub-Saharan Africa.




Fig. 2. SMIM1 protein. a. The schematic of the SMIM1 protein with I-TASSER predicted 3D-structure showing the extracellular domain (green), transmembrane helix (yellow) and the cytosolic domain (blue) b. Amino acids sequence of the human SMIM1 showing the confirmed different phosphorylation sites (Black) amidst the cytosolic domain (green), transmembrane domain (red) and the extracellular domain (cyan).

Currently, no pathophysiological condition has been associated with the lack of SMIM1 in humans, largely attributable to the lack of the physiological function of the antigen. However experiments in zebra fish associated the absence of the protein to low hemoglobin levels (Cvejic et al., 2013). Given that the absence of some blood group antigens results in pathologies ranging from mild to life threatening conditions (Mohandas and Narla, 2005; Amjadi et al., 2015), it is worthwhile to comprehensively identify and classify all possible genetic signatures that account for non-expression or varied expression of SMIM1 in heterogeneous populations. In addition, based on data from the zebra fish experiment, it is logical to investigate any possible pathophysiological condition associated with the lack of SMIM1.

5. Typing the Vel blood group

Pre-sensitized Vel⁻ patients are at risk of suffering acute hemolytic reaction should they be mistakenly transfused with Vel positive blood. Similarly, sensitized pregnant women risk losing a Vel⁺ fetus through hemolytic diseases of the fetus and newborn. These clinical implications of sensitization in Vel⁻ individuals highlight the need to properly identify the Vel status of primigravida women as well as both donor blood and the corresponding recipients. However, there is wide variation in the levels of expression of SMIM1, especially in individuals who are heterozygous for the 17 bp deletion (Ballif et al., 2013; Cvejic et al., 2013; Storry et al., 2013). Furthermore, before the identification of SMIM1 as expressing the Vel antigen, serology was the only means of typing Vel. However, this approach was quite cumbersome and in some cases unreliable largely because (a) anti-Vel antibodies could only be obtained from the serum of sensitized Vel⁻ individuals, and (b) the expression of the Vel antigen varies significantly among individuals, ranging from high, low (weak) to no expression. Thus, there was the risk of typing a weak expresser as negative.

The varied expressivity of Vel (SMIM1), together with scarcity of antibodies to the antigen made serological typing unreliable. However, identification of the genetic basis of the Vel blood group has led to the development of genetic techniques for typing the Vel antigen (Ballif et al., 2013; Wieckhusen et al., 2015; Costa et al., 2016; Dezan et al., 2016). Additionally, the successful production of anti-Vel monoclonal antibodies (Danger et al., 2016) provides a reliable source of reagents for antibody-based molecular analysis. Another method that was recently used in typing Vel and the different genotypes at rs1175550 (A/G) among Thai donors employed Matrix-Assisted Laser Desorption Ionization coupled Time-of-flight mass spectrometry (MALDI-TOF MS) (Jongruamklang et al., 2018). Much as this method is good, it is limited by the cost as well as proximity to the blood group typing centers. In this study, the investigators identified the variable expression of SMIM1 (Vel) in positive individuals which points to the inaccuracy of serology for distinguishing low SMIM1 (Vel) expressing individuals from negatives (Chandanayingyong et al., 1967). Such variations in SMIM1 expression can easily be determined using flow cytometry (Dezan et al., 2016). The allele-specific and restriction fragment length polymorphism (RFLP) PCR-based methods are robust and can be applied in high throughput for the successful characterization of the Vel genotypes, thus, making Vel typing in both clinical practice and research easy and reliable. However, there are currently no commercially available Vel genotyping platforms for use outside reference/research laboratories, thus making this technology less accessible for clinical application.

6. SMIM1 in the *Plasmodium falciparum* infection

The malaria parasite *Plasmodium*, is among a limited number of disease-causing agents that reside in human erythrocytes (Rios and Bianca, 2000). Various aspects of parasite development and disease pathology have been attributed to blood group antigens. For instance, *Plasmodium vivax* requires the Duffy antigen to successfully invade reticulocytes; *P. falciparum* requires the sialic acid moieties on glycoporphins, in addition to other receptors such as complement receptor 1 (CR1), decay accelerating factor (DAF), basigin, and band-3, for entry into host erythrocytes (Egan, 2018). Disease phenotypes such as rosette formation are thought to be influenced by the ABO blood group, where by O individuals being lower risk of severe malaria while group A are more predisposed individuals to severe malaria (Barragan et al., 2000; Rowe et al., 2007; Vigan-Womas et al., 2012; Goel et al., 2015; Mancio-Silva and Mota, 2015). These are a few examples of the critical roles blood group antigens play in malaria pathogenesis in humans.

In their seminal article, Storry and colleagues showed that SMIM1 protein shares similar biochemical properties with the glycoporphins, especially, glycoporphin A (GPA) (Storry et al., 2013). These included SMIM1 exhibiting properties of a type I transmembrane protein, possession of possible glycosylation sites and a transmembrane domain with a dimerization motif. This led them to propose a possible function of SMIM1 as a *P. falciparum* invasion mediating receptor. SMIM1 has however been shown to be a type II transmembrane protein (Arnaud et al., 2015). Nonetheless, the protein contains phosphorylation sites within the cytoplasmic region (Arnaud et al., 2015), reminiscent of erythrocyte membrane proteins which have been implicated in *P. falciparum* invasion and development in human erythrocytes (Aniwah et al., 2017). Also, SMIM1 is seen to be phosphorylated in erythrocytes infected with *P. falciparum* schizont stages (Solyakov et al., 2011). *P. falciparum* infection-induced phosphorylation of erythrocyte membrane proteins such as band 3 is known to be critical for parasite egress (Kesely et al., 2016; Pantaleo et al., 2017), possibly due to weakening of the membrane as a result of phosphorylated band 3 dissociating from the cytoskeleton leading to disruption of the membrane's cytoskeletal organization (Ferru et al., 2011). Structurally, it has previously been suggested that the SMIM1 forms part of the same junctional membrane complex with glycoporphin C, the Rh antigen and the Kell glycoprotein (Issitt et al., 1994; Daniels, 2013). Given the possible connection between SMIM1 and the structural organization of the erythrocyte membrane, its phosphorylation in *P. falciparum* infected erythrocytes and the similarities shared with the glycoporphins, its potential role in *P. falciparum* infection requires further investigations.

The malaria parasite is one of the most successful human parasites, and arguably the most selective force on the evolution of the human genome. Conditions such as sickle cell anemia, glucose-6-phosphate dehydrogenase deficiency, and thalassemia have direct correlations with the incidence of malaria (Fortin et al., 2002; Kwiatkowski, 2005; Parikh and Rosenthal, 2008; Anstee, 2010; Egan, 2018). Notwithstanding, the presence of the malaria parasite impacts the expression and extent of sequence variation of erythrocyte surface receptor genes (Mayer et al., 2004; Kwiatkowski, 2005; Ko et al., 2011; Idaghdour et al., 2012; Network, 2015; Dankwa et al., 2017; Leffler et al., 2017). Notably, the absence of the duffy antigen/chemokine receptor CD234 (DARC) in most Africans is believed to be an evolutionary response to *P. vivax* infection (Chitnis and Miller, 1994; Kwiatkowski, 2005). Similarly, the high rate of polymorphisms in the glycoporphins, and other invasion-mediating erythrocyte surface receptors in people living in malaria endemic regions is thought to be an adaptation against parasite assault on the erythrocytes (Mayer et al., 2004; Kwiatkowski, 2005). Given the possible involvement of SMIM1 in malaria pathogenesis, it is likely that this gene is under selection in the sub-Saharan African population and thus may exhibit distinct genetics different from those currently known. A recent study in Kenyan children however did not associate SMIM1 polymorphisms with severe malaria (Ndila et al., 2018). Nonetheless, this does not rule out SMIM1 being involved in parasite development. Historically, despite their role in malaria pathogenesis being ascertained by molecular and biochemical studies, erythrocyte surface receptors have been under-represented in genome-wide association studies aimed at identifying signatures of protection against malaria (Egan, 2018). The observation by Ndila et al. could mean that (a) SMIM1 is not involved in malaria pathogenesis; (b) the malaria parasite is not a selectable force on the gene; (c) SMIM1 is functionally conserved and thus less polymorphic; (d) the gene is diverse such that the contribution of individual haplotypes were masked in the gene pool. Critical examination of SMIM1 genetics in a heterogeneous population such as that of Africans would provide insight into the possible function and evolution of this gene.

7. Conclusion

Currently, there are limited data on Vel prevalence and SMIM1 genetics in sub-Saharan Africa as well as other populations. The only available data, thus far, were obtained from parts of Europe, Ethiopia and South Africa (Haer-Wigman et al., 2015a, 2015b). However, these data are very limited and lack the power to make a valid argument of geo-specific prevalence of the blood group. Given evidence provided herein; including (a) lack of linkage between the reference SNPs (rs1175550G and rs143702418CGCA) in people of black descent in comparison to Caucasians; (b) the possible role of SMIM1 in malaria pathogenesis; and (c) the selective pressure malaria exerts on the human genome, suffice it to hypothesize that SMIM1 expression and its genetics in sub-Saharan Africa may differ from currently available data on this fascinating erythrocyte surface antigen. It is imperative to combine genotypic data on the Vel blood group together with phenotypic data to understand its variability in specific populations. As a protein expressed on the surface of both erythroid precursor cells and mature erythrocytes, it is necessary to understand the extent to which the protein functions in connection with the erythrocyte cytoskeleton as well as membrane associated proteins. In addition, the differential interactions that are affected by the phosphorylation of SMIM1 will be necessary to establish its role on the erythrocyte.

Acknowledgments

We thank Prof. Kirk W. Deistch of Weill Cornell Medical College for taking time to edit this manuscript, Jonathan Subaar for providing technical support for this work and members of the Cell Biology and Immunology laboratory at WACCBIP for their individual contributions to this review.

Funding

This work was supported by funds from a World Bank African Centres of Excellence grant (ACE02-WACCBIP: Awandare) and a DELTAS Africa grant (DEL-15-007: Awandare). Prince Berko Nyarko and Evelyn Quansah were supported by WACCBIP-World Bank ACE Masters' fellowships; Laty Gaye Thiam was supported by a WACCBIP-World Bank ACE PhD fellowship, while Yaw Aniweh was supported by a WACCBIP-DELTAS postdoctoral fellowship. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences's (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (107755/Z/15/Z: Awandare) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

References

- Amjadi, O., Rafiei, A., Ajami, A., Valadan, R., Janbaabaei, G., 2015. Blood groups: in health and diseases. *Research in Molecular Medicine* 3 (4), 1–9.
- Aniweh, Y., Gao, X., Hao, P., Meng, W., Lai, S. K., Gunalan, K., Chu, T. T., Sinha, A., Lescar, J. and Chandramohanadas, R. (2017). P. falciparum RH5-Basigin interaction induces changes in the cytoskeleton of the host RBC. *Cellular Microbiology*.
- Anstee, D. J. (2010). The relationship between blood groups and disease. *Blood*, blood-2010-2001-261859.
- Arnaud, L., Kelley, L.P., Helias, V., Cartron, J.P., Ballif, B.A., 2015. SMIM1 is a type II transmembrane phosphoprotein and displays the Vel blood group antigen at its carboxyl-terminus. *FEBS Lett.* 589 (23), 3624–3630. <https://doi.org/10.1016/j.febslet.2015.09.029>.
- Ballif, B.A., Helias, V., Peyrard, T., Menanteau, C., Saison, C., Lucien, N., Bourgouin, S., Le Gall, M., Cartron, J.P., Arnaud, L., 2013. Disruption of SMIM1 causes the Vel-blood type. *EMBO Mol Med* 5 (5), 751–761. <https://doi.org/10.1002/emmm.201302466>.

- Barragan, A., Kremsner, P.G., Wahlgren, M., Carlson, J., 2000. Blood group A antigen is a coreceptor in *Plasmodium falciparum* Rosetting. *Infect. Immun.* 68 (5), 2971–2975.
- Cedergren, B., Giles, C.M., Ikin, E.W., 1976. The Vel blood group in northern Sweden. *Vox Sang.* 31 (5), 344–355.
- Chandanayingyong, D., Sasaki, T.T., Greenwalt, T.J., 1967. Blood groups of the Thais. *Transfusion* 7 (4), 269–276.
- Chitnis, C.E., Miller, L.H., 1994. Identification of the erythrocyte binding domains of *Plasmodium vivax* and *Plasmodium knowlesi* proteins involved in erythrocyte invasion. *J. Exp. Med.* 180 (2), 497–506.
- Christophersen, M.K., Jöud, M., Ajore, R., Vege, S., Ljungdahl, K.W., Westhoff, C.M., Olsson, M.L., Storry, J.R., Nilsson, B., 2017. SMIM1 variants rs1175550 and rs143702418 independently modulate Vel blood group antigen expression. *Sci. Rep.* 7, 40451.
- Costa, D.C., Dezan, M., Santos, T., Schinaider, A.A., Schorner, E.J., Levi, J.E., Santos-Silva, M.C., 2016. Screening for the SMIM1*64_80 del allele in blood donors in a population from Southern Brazil. *Transfus. Med.* 26 (5), 355–359. <https://doi.org/10.1111/tme.12328>.
- Cvejic, A., Haer-Wigman, L., Stephens, J.C., Kostadima, M., Smethurst, P.A., Frontini, M., Van Den Akker, E., Bertone, P., Bielczyk-Maczynska, E., Farrow, S., et al., 2013. SMIM1 underlies the Vel blood group and influences red blood cell traits. *Nat. Genet.* 45 (5), 542–545. <https://doi.org/10.1038/ng.2603>.
- Danger, Y., Danard, S., Gringoire, V., Peyrard, T., Riou, P., Semana, G., Verite, F., 2016. Characterization of a new human monoclonal antibody directed against the Vel antigen. *Vox Sang.* 110 (2), 172–178. <https://doi.org/10.1111/vox.12321>.
- Daniels, G. (2013). *Human Blood Groups*. 3rd ed. Oxford: Wiley-Blackwell.
- Dankwa, S., Chaand, M., Kanjee, U., Jiang, R.H., Nobre, L.V., Goldberg, J.M., Bei, A.K., Moechtar, M.A., Grüning, C., Ahouidi, A.D., 2017. Genetic evidence for erythrocyte receptor glycoporphin B expression levels defining a dominant *Plasmodium falciparum* invasion pathway into human erythrocytes. *Infect. Immun.* 85 (10), e00074–17.
- Dezan, M.R., Dinardo, C.L., Bosi, S.R., Vega, S., Salles, N.A., Mendrone-Junior, A., Levi, J.E., 2016. High-throughput strategy for molecular identification of Vel— blood donors employing nucleic acids extracted from plasma pools used for viral nucleic acid test screening. *Transfusion* 56 (6), 1430–1434. <https://doi.org/10.1111/trf.13572>.
- Egan, E.S., 2018. Beyond hemoglobin: screening for malaria host factors. *Trends Genet.* 34 (2), 133–141. <https://www.sciencedirect.com/science/article/pii/S0168952517302068?via%3Dihub>.
- Fehrmann, R.S., Jansen, R.C., Veldink, J.H., Westra, H.-J., Arends, D., Bonder, M.J., Fu, J., Deelen, P., Groen, H.J., Smolonska, A., 2011. Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. *PLoS Genet.* 7 (8), e1002197.
- Ferru, E., Giger, K., Pantaleo, A., Campanella, E., Grey, J., Ritchie, K., Vono, R., Turrini, F. and Low, P. S. (2011). Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3. *Blood*, blood-2010-2011-317024.
- Fortin, A., Stevenson, M., Gros, P., 2002. Susceptibility to malaria as a complex trait: big pressure from a tiny creature. *Hum. Mol. Genet.* 11 (20), 2469–2478.
- Goel, S., Palmkvist, M., Moll, K., Joannin, N., Lara, P., Akhoury, R.R., Moradi, N., Öjemalm, K., Westman, M., Angeletti, D., 2015. RIFINs are adhesins implicated in severe *Plasmodium falciparum* malaria. *Nat. Med.* 21 (4), 314.
- Haer-Wigman, L., Stegmann, T. C., Solati, S., Ait Soussan, A., Beckers, E., Van Der Harst, P., Van Hulst-Sundermeijer, M., Ligthart, P., Van Rhenen, D. and Schepers, H. (2015a). Impact of genetic variation in the SMIM1 gene on Vel expression levels. *Transfusion*, 55(6pt2), 1457–1466.
- Haer-Wigman, L., Stegmann, T.C., Solati, S., Ait Soussan, A., Beckers, E., Van Der Harst, P., Van Hulst-Sundermeijer, M., Ligthart, P., Van Rhenen, D., Schepers, H., et al., 2015b. Impact of genetic variation in the SMIM1 gene on Vel expression levels. *Transfusion* 55 (6 Pt 2), 1457–1466. <https://doi.org/10.1111/trf.13014>.
- Herron, R., Hyde, R., Hillier, S., 1979. The second example of an anti-Vel auto-antibody. *Vox Sang.* 36 (3), 179–181.
- Idaghdour, Y., Quinlan, J., Goulet, J.-P., Berghout, J., Gbeha, E., Bruat, V., De Malliard, T., Grenier, J.-C., Gomez, S., Gros, P., 2012. Evidence for additive and interaction effects of host genotype and infection in malaria. *Proc. Natl. Acad. Sci.* 109 (42), 16786–16793.
- Issitt, P., Combs, M., Carawan, H., Kirkland, A., Allen, J., Telen, M., Bullock, R., Soles, L., Wright, T., 1994. Phenotypic Association Between Ge and Vel (Paper Presented at the Transfusion).
- Jongruamklang, P., Gassner, C., Meyer, S., Kummasook, A., Darlison, M., Boonlum, C., Chanta, S., Frey, B.M., Olsson, M.L., Storry, J.R., 2018. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of 36 blood group alleles among 396 Thai samples reveals region-specific variants. *Transfusion*. <https://doi.org/10.1111/trf.14624>.
- Kesely, K.R., Pantaleo, A., Turrini, F.M., Olupot-Olupot, P., Low, P.S., 2016. Inhibition of an erythrocyte tyrosine kinase with imatinib prevents *Plasmodium falciparum* egress and terminates parasitemia. *PLoS One* 11 (10), e0164895.
- Ko, W.-Y., Kaercher, K.A., Giombini, E., Marcatili, P., Froment, A., Ibrahim, M., Lema, G., Nyambo, T.B., Omar, S.A., Wambebe, C., 2011. Effects of natural selection and gene conversion on the evolution of human glycoporphins coding for MNS blood polymorphisms in malaria-endemic African populations. *Am. J. Hum. Genet.* 88 (6), 741–754.
- Kwiatkowski, D.P., 2005. How malaria has affected the human genome and what human genetics can teach us about malaria. *Am. J. Hum. Genet.* 77 (2), 171–192.
- Le Masne, A., Vachee, A., Horbey, C., Mannessier, L., Gruca, L., Rouland, V., Lequien, P., 1992. Severe form of neonatal hemolytic disease by anti-Vel allo-immunization. *Arch. Fr. Pédiatr.* 49 (10), 899–901.
- Leffler, E. M., Band, G., Busby, G. B., Kivinen, K., Le, Q. S., Clarke, G. M., Bojang, K. A., Conway, D. J., Jallow, M. and Sisay-Joof, F. (2017). Resistance to malaria through structural variation of red blood cell invasion receptors. *Science*, 356(6343), eaam6393.
- Levine, P., Robinson, E.A., Herrington, L.B., Sussman, L.N., 1955. Second example of the antibody for the high-incidence blood factor Vel. *Am. J. Clin. Pathol.* 25 (7), 751–754.
- Mancio-Silva, L., Mota, M.M., 2015. A mediator for malaria stickiness in A versus O blood. *Nat. Med.* 21 (4), 307.
- Mayer, D.G., Mu, J.-B., Kaneko, O., Duan, J., Su, X.-Z., Miller, L.H., 2004. Polymorphism in the *Plasmodium falciparum* erythrocyte-binding ligand JESEBL/EBA-181 alters its receptor specificity. *Proc. Natl. Acad. Sci. U. S. A.* 101 (8), 2518–2523.
- Mohandas, N., Narla, A., 2005. Blood group antigens in health and disease. *Curr. Opin. Hematol.* 12 (2), 135–140.
- Ndila, C.M., Uyoga, S., Macharia, A.W., Nyutu, G., Peshu, N., Ojal, J., Shebe, M., Awoondo, K.O., Mhuri, N., Tsofa, B., 2018. Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. *The Lancet Haematology* 5 (8), e333–e345.
- Network, M.G.E., 2015. A novel locus of resistance to severe malaria in a region of ancient balancing selection. *Nature* 526 (7572), 253.
- Pantaleo, A., Kesely, K. R., Pau, M. C., Tsamesidis, I., Schwarzer, E., Skorokhod, O. A., Chien, H. D., Ponzi, M., Bertuccini, L. and Low, P. S. (2017). Syk inhibitors interfere with erythrocyte membrane modification during P. falciparum growth and suppress parasite egress. *Blood*, blood-2016-2011-748053.
- Parikh, S., Rosenthal, P.J., 2008. *Human Genetics and Malaria: Relevance for the Design of Clinical Trials*. The University of Chicago Press, In.
- Rios, M., Bianca, C., 2000. *The Role of Blood Group Antigens in Infectious Diseases* (Paper Presented at the Seminars in Hematology).
- Rowe, J.A., Handel, I.G., Thera, M.A., Deans, A.-M., Lyke, K.E., Koné, A., Diallo, D.A., Raza, A., Kai, O., Marsh, K., 2007. Blood group O protects against severe *Plasmodium falciparum* malaria through the mechanism of reduced rosetting. *Proc. Natl. Acad. Sci.* 104 (44), 17471–17476.
- Solyakov, L., Halbert, J., Alam, M.M., Semblat, J.-P., Dorin-Semblat, D., Reininger, L., Bottrill, A.R., Mistry, S., Abdi, A., Fennell, C., 2011. Global kinomic and phosphoproteomic analyses of the human malaria parasite *Plasmodium falciparum*. *Nat. Commun.* 2, 565.
- Storry, J., Peyrard, T., 2017. The Vel blood group system: a review. *Immunohematology* 33 (2), 56–59.
- Storry, J.R., Joud, M., Christophersen, M.K., Thuresson, B., Sojka, B.N., Nilsson, B., Olsson, M.L., 2013. Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype. *Nat. Genet.* 45 (5), 537–541. <https://doi.org/10.1038/ng.2600>.
- Sussman, L.N., 1962. Current status of the Vel blood group system. *Transfusion* 2 (3), 163–171.
- Sussman, L., Miller, E., 1952. New blood factor: Vel. *Revue d'hématologie* 7 (3), 368.
- Szalóky, A., Van Der Hart, M., 1971. An auto-antibody anti-Vel. *Vox Sang.* 20, 376–377.
- Van Der Harst, P., Zhang, W., Leach, I.M., Rendon, A., Verweij, N., Sehmi, J., Paul, D.S., Elling, U., Allayee, H., Li, X., 2012. Seventy-five genetic loci influencing the human red blood cell. *Nature* 492 (7429), 369.
- Van Gammeren, A.J., Overbeeke, M.A., Idema, R.N., Van Beek, R.H., Ten Kate-Booij, M.J., Ermens, A.A., 2008. Haemolytic disease of the newborn because of rare anti-Vel. *Transfus. Med.* 18 (3), 197–198. <https://doi.org/10.1111/j.1365-3148.2008.00863.x>.

- Vigan-Womas, I., Guillotte, M., Juillerat, A., Hessel, A., Raynal, B., England, P., Cohen, J.H., Bertrand, O., Peyrard, T., Bentley, G.A., 2012. Structural basis for the ABO blood-group dependence of *Plasmodium falciparum* rosetting. *PLoS Pathog.* 8 (7), e1002781.
- Vucinovic, M., Jadric, H., Karelavic, D., Roje, D., Haspl-Hundric, Z., Hrgovic, Z., Vucinovic, Z., 2004. Haemolytic disease of the newborn—from a mother with anti-Kell, anti-E and anti-Vel anti-erythrocyte alloantibodies. *Z. Geburtshilfe Neonatol.* 208 (5), 197–202. <https://doi.org/10.1055/s-2004-832639>.
- Wieckhusen, C., Rink, G., Scharberg, E.A., Rothenberger, S., Komurcu, N., Bugert, P., 2015. Molecular screening for Vel-blood donors in southwestern Germany. *Transfus. Med. Hemother.* 42 (6), 356–360. <https://doi.org/10.1159/000440791>.